Citations

Showing 10 of 108152 citations.

EPA and DHA elicit distinct transcriptional responses to high-fat feeding in skeletal muscle and liver
Kunz, Hawley , Dasari, Surendra , Lanza, Ian R. , Kunz, Hawley E., Lanza, Ian R , Kunz, Hawley E

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | July 2, 2019 | Volume: 317 | Issue: 3 | Pages: E460-E472

10.1152/ajpendo.00083.2019 | PMID 31265326 Get It

Omega-3 polyunsaturated fatty acids ( n-3 PUFAs) exert numerous beneficial biological effects and attenuate diet-induced insulin resistance in rodent models. In the present study, the independent, tissue-specific effects of two nutritionally relevant n-3 PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), were characterized in the context of a high-fat diet (HFD). EPA and DHA supplementation (3.2% of total fat) in 6-mo-old male C57BL/6 mice fed an HFD (60% fat) partially mitigated reductions in insulin sensitivity. At 5 wk, the area above the curve below baseline glucose following an intraperitoneal insulin tolerance test was 54.5% lower in HFD than control, whereas HFD + EPA and HFD + DHA showed 27.6% and 17.1% reductions, respectively. At 10 wk, HFD increased mitochondrial oxidative capacity supported by lipid and carbohydrate-based substrates in both liver and skeletal muscle ( P < 0.05), with little effect of EPA or DHA supplementation. Whole genome transcriptomic analyses revealed HFD-induced transcriptional changes indicative of inflammation and fibrosis in both liver and muscle. Gene set enrichment analyses indicated a downregulation of transcripts associated with extracellular matrix in muscle (family-wise error rate P < 0.01) and liver ( P = 0.04) and in transcripts associated with inflammation in muscle ( P = 0.03) in HFD + DHA compared with HFD alone. In contrast, EPA appeared to potentiate some proinflammatory effects of the HFD. In the skeletal muscle, DHA increased the expression of stress-responsive genes, whereas EPA upregulated the expression of transcripts related to cell cycle. Therefore, although both EPA and DHA supplementation during HFD partially preserve insulin signaling, they modulate distinct processes, highlighting their unique biological effects in the context of obesity.
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway
Kothari, Vishal , Goodwin, Jonathan F., Zhao, Shuang G. , Chang, S. Laura , Evans, Joseph R. , Wilder-Romans, Kari , Gabbara, Kristina M., Dylgjeri, Emanuela , Sun, Grace Y., Tomlins, Scott A. , Mehra, Rohit , Hege, Kristen , Filvaroff, Ellen, Schaeffer, Edward M. , Karnes, R. Jeffrey , Quigley, David A. , Speers, Corey , Spratt, Daniel E. , Gilbert, Luke A. , Ashworth, Alan , Chinnaiyan, Arul M., Raj, Ganesh V. , Feng, Felix Y. , Speers, Corey , Spratt, Daniel E , Zhao, Shuang G , Drake, Justin M , Yin, Yi Ming , Chou, Jonathan , Rathkopf, Dana E , He, Housheng Hansen , Knudsen, Karen E.

Mayo Clinic

Clinical Cancer Research | July 2, 2019 | Volume: 25 | Issue: 18 | Pages: 5608-5622

10.1158/1078-0432.ccr-18-2387 | PMID 31266829 Get It

Abstract Purpose: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo. Results: DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription. Conclusions: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Latin American and Spanish-speaking perspectives on the challenges of global psychiatry
Alarcón, Renato D. , Stepke, Fernando Lolas , Mari, Jair de Jesus , Lázaro, José Portolés , Baca‐Baldomero, Enrique, Mari, Jair J , Lázaro, José

Mayo Clinic

Brazilian Journal of Psychiatry | July 2, 2019 | Volume: 42 | Issue: 1 | Pages: 77-86

10.1590/1516-4446-2018-0397 | PMID 31269096 Get It

Cellular models of alpha‐synuclein toxicity and aggregation
Delenclos, Marion , Burgess, Jeremy D. , Lamprokostopoulou, Agaristi , Outeiro, Tiago F. , Vekrellis, Kostas , McLean, Pamela J. , McLean, Pamela J , Vekrellis, Kostas , McLean, Pamela J

Mayo Clinic

Journal of Neurochemistry | July 2, 2019 | Volume: 150 | Issue: 5 | Pages: 566-576

10.1111/jnc.14806 | PMID 31265132 Get It

AbstractMisfolding and aggregation of alpha‐synuclein (α‐synuclein) with concomitant cytotoxicity is a hallmark of Lewy body related disorders such as Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy. Although it plays a pivotal role in pathogenesis and disease progression, the function of α‐synuclein and the molecular mechanisms underlying α‐synuclein‐induced neurotoxicity in these diseases are still elusive. Many in vitro and in vivo experimental models mimicking α‐synuclein pathology such as oligomerization, toxicity and more recently neuronal propagation have been generated over the years. In particular, cellular models have been crucial for our comprehension of the pathogenic process of the disease and are beneficial for screening of molecules capable of modulating α‐synuclein toxicity. Here, we review α‐synuclein based cell culture models that reproduce some features of the neuronal populations affected in patients, from basic unicellular organisms to mammalian cell lines and primary neurons, to the cutting edge models of patient‐specific cell lines. These reprogrammed cells known as induced pluripotent stem cells (iPSCs) have garnered attention because they closely reproduce the characteristics of neurons found in patients and provide a valuable tool for mechanistic studies. We also discuss how different cell models may constitute powerful tools for high‐throughput screening of molecules capable of modulating α‐synuclein toxicity and prevention of its propagation. image This article is part of the Special Issue “Synuclein”.
Mycobacterium scrofulaceum disease: experience from a tertiary medical centre and review of the literature
Wilson, John , Jagtiani, Anil, Wengenack, Nancy L.

Mayo Clinic

Infectious Diseases | July 2, 2019 | Volume: 51 | Issue: 8 | Pages: 602-609

10.1080/23744235.2019.1634281 | PMID 31264491 Get It

Glucose Control in the Perioperative Period—Reply
Simha, Vinaya , Shah, Pankaj, Shah, Pankaj

Mayo Clinic

JAMA | July 2, 2019 | Volume: 322 | Issue: 1 | Pages: 82

10.1001/jama.2019.5852 | PMID 31265096 Get It

Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections
McDonald, Jennifer S. , Kolbe, Amy B. , Schmitz, John J. , Hartman, Robert P. , Kallmes, David F. , McDonald, Robert J. , Hunt, Christopher H , Schmitz, John J , Maddox, Daniel E. , Kallmes, David F , Hunt, Christopher H.

Mayo Clinic

Radiology | July 2, 2019 | Volume: 292 | Issue: 3 | Pages: 620-627

10.1148/radiol.2019182834 | PMID 31264948 Get It

SCN5A mutation G615E results in NaV1.5 voltage-gated sodium channels with normal voltage-dependent function yet loss of mechanosensitivity
Strege, Peter R. , Mercado‐Perez, Arnaldo , Mazzone, Amelia , Saito, Yuri A. , Bernard, Cheryl E., Farrugia, Gianrico , Strege, Peter R , Mazzone, Amelia , Beyder, Arthur

Mayo Clinic

Channels | July 2, 2019 | Volume: 13 | Issue: 1 | Pages: 287-298

10.1080/19336950.2019.1632670 | PMID 31262209 Get It

Increased stride‐rate in runners following an independent retraining program: A randomized controlled trial
Baumgartner, Jesson , Gusmer, Rebecca, Hollman, John H. , Finnoff, Jonathan T. , Hollman, John , Finnoff, Jonathan T

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | July 2, 2019 | Volume: 29 | Issue: 11 | Pages: 1789-1796

10.1111/sms.13509 | PMID 31264286 Get It

PurposeIncreasing stride‐rate by 5%‐10% has been used for injury prevention and rehabilitation but evidence is limited if an independent program can alter stride‐rate in runners. The objective of this study was to determine whether the preferred stride‐rate of recreational runners can be increased by 5%‐10% following a 6‐week independent training program.MethodsThirty‐eight runners running a minimum of 15 miles/wk with a preferred stride‐rate ≤85 strides/min determined during treadmill testing were randomized into two groups: (a) Experimental group was instructed to increase stride‐rate by 10% using a watch and foot pod for stride‐rate feedback; and (b) Control group was instructed to continue normal running. Compliance was tracked with a training log. One stride being defined as two sequential steps. Preferred running stride‐rate was retested at 6 weeks using the same testing protocol.ResultsThere was no significant difference in baseline preferred running stride‐rates between the experimental or control groups. A significant (P < .001) increase in stride‐rate from 79.9 ± 4.8 to 86.8 ± 5.7 strides/min (8.6% increase) was found in the experimental group. The control group did not significantly change their stride‐rate (Baseline: 80.4 ± 4.2, 6 weeks: 81.3 ± 3.3 strides/min).ConclusionA 6‐week home training program using a watch and foot pod can increase the preferred running stride‐rate by 5%‐10% in runners with a stride‐rate of 85 or less. Clinicians may be able to apply this type of gait retraining in recreational runners when designing injury prevention and rehabilitation programs.
Applying to Plastic Surgery Residency While In-Recovery From Skull Base Excision
Oliver, Jeremie D. , Oliver, Jeremie D

Mayo Clinic

The Cleft Palate Craniofacial Journal | July 2, 2019 | Volume: 56 | Issue: 9 | Pages: 1263-1263

10.1177/1055665619859753 | PMID 31262186 Get It